What is Nabota and how does it compare to Botox?

Nabota is a botulinum toxin produced by Korean pharmaceutical company Daewoong that competes directly with Allergan's Botox and Galderma's Dysport. It offers competitive pricing and has gained regulatory approval across multiple markets, particularly in Asia-Pacific and the Middle East, making it an alternative for practices seeking supply diversity or cost optimization.

Is Nabota available in the United States?

Nabota is not currently approved by the FDA for use in the United States, though it has secured regulatory clearance in seven GCC markets and across Asia-Pacific. U.S. practices should monitor its regulatory trajectory, as Daewoong's aggressive international expansion may eventually lead to domestic market entry.

Why is Daewoong expanding Nabota across the Middle East?

The GCC region offers high aesthetic procedure volume, strong pricing power, and limited regulatory friction—making it attractive for market expansion. Daewoong's completion of all seven GCC markets signals confidence in competing against Allergan and Galderma in regions where brand loyalty is still forming and pricing is not yet commoditized.

What other Korean botulinum toxin brands are competing globally?

Beyond Daewoong's Nabota, Korean manufacturers Hugel and Medytox are also expanding internationally with their own botulinum toxin products. These competitors offer similar advantages: competitive pricing and established regulatory pathways in emerging markets where Allergan's dominance is weakening.

How does Nabota's expansion affect U.S. medical aesthetics practices?

Nabota's Middle East sweep demonstrates that the global toxin market is fragmenting away from Allergan's historical dominance, particularly in emerging markets. Practices with international operations or supply-chain concerns should monitor Nabota's regulatory progress, as increased competition may eventually influence domestic pricing and availability.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Market

Daewoong's Nabota Enters Kuwait—Completes 7-Market GCC Sweep

Korean toxin expands across Middle East, signaling aggressive international push and competitive pressure on Allergan and Galderma in high-margin markets.

By Evan at Inside MedSpa · Jul 31, 2026

1-YEAR MOVE

ABBV ▲11.6%

1-year price move by ticker
Ticker	Company	1-year change
ABBV	AbbVie (Allergan Aesthetics)	+11.6%

Daewoong Pharmaceutical announced that its botulinum toxin Nabota has entered Kuwait, marking the seventh Middle Eastern market for the Korean competitor. The expansion completes a strategic sweep of Gulf Cooperation Council (GCC) markets—a region characterized by high aesthetic procedure volume, strong pricing power, and limited regulatory friction.

Nabota has been steadily building international market share, particularly in Asia-Pacific and now the Middle East. The product's entry into Kuwait signals Daewoong's confidence in competing head-to-head with Allergan Aesthetics (Botox) and Galderma (Dysport) in markets where brand loyalty is still forming and pricing is not yet commoditized.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/daewoong-nabota-kuwait-seventh-middle-east-market/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

Daewoong's Nabota Enters Kuwait—Completes 7-Market GCC Sweep

Share

Discussion

Leave a comment

By the time it's news, it's too late.